^
Association details:
| Biomarker: | BRCA mutation |
|---|---|
| Cancer: | Diffuse Large B Cell Lymphoma |
| Drug: | Zynlonta (loncastuximab tesirine-lpyl) (DNA replication inhibitor, CD19-targeted antibody-drug conjugate) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
CD19-Mediated DNA Damage Boost in Lymphoma Cells Treated with Loncastuximab Tesirine in Combination with PARP Inhibitors
Published date:
11/04/2021
Excerpt:
Lonca showed significant cytotoxic activity in 10 of 13 cell lines, which were sensitive in the same range of clinically achievable concentrations, with IC50 values ≤ 1 ng/ml...Interestingly, BRCA-mutated DOHH2 cells were highly sensitive to single agent Lonca...
DOI:
10.1182/blood-2021-150464
